Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPEP | Q07075 | 4/20 | 0.46 |
| ▸ | GRIK1 | P39086 | 5/20 | 0.39 |
| ▸ | GRIK2 | Q13002 | 5/20 | 0.39 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.35 |
| ▸ | SLC1A1 | P43005 | 4/20 | 0.34 |
| ▸ | SLC1A2 | P43004 | 5/20 | 0.33 |
| ▸ | SLC1A3 | P43003 | 4/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | GRM8 | O00222 | 1/20 | 0.32 |
| ▸ | GRM6 | O15303 | 1/20 | 0.32 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.32 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.32 |
| ▸ | GSR | P00390 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16111088 | 0.82 | SLC7A5 (0.52) | GRIK1GRIK2SLC7A5PTGS1SLC7A11 | |
| SCHEMBL27857208 | 0.82 | SLC7A5 (0.52) | GRIK1GRIK2SLC7A5PTGS1SLC7A11 | |
| SCHEMBL10888010 | 0.78 | FOLH1 (0.39) | ENPEPGRIK1GRIK2SLC7A5PTGS1 | |
| SCHEMBL7468398 | 0.73 | SLC1A2 (0.35) | ENPEPGRIK1GRIK2SLC7A5PTGS1 | |
| SCHEMBL27404117 | 0.71 | ENPEP (0.70) | ENPEPGRIK1GRIK2SLC7A5PTGS1 | |
| SCHEMBL27279258 | 0.71 | SLC1A1 (0.31) | SLC1A1 | |
| SCHEMBL8535 | 0.70 | — | — | |
| SCHEMBL5320674 | 0.70 | — | — | |
| SCHEMBL4957102 | 0.70 | — | — | |
| SCHEMBL786927 | 0.69 | ENPEP (0.50) | ENPEPSLC7A5ALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192896-A1 | BISPECIFIC ANTIBODIES BINDING TO COAGULATION FACTOR IX AND COAGULATION FACTOR X | BIOVERATIV THERAPEUTICS INC (US) | 2023-06-22 | — | — | US | disclosed |
| US-20220324922-A1 | CONUS-BASED TOXIN PEPTIDES, NUCLEIC ACIDS ENCODING SAME AND USES THEREOF IN MODULATING NMDA RECEPTORS | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2022-10-13 | — | — | US | disclosed |
| EP-3663399-B1 | MODIFIED FACTOR IX POLYPEPTIDES AND USES THEREOF | CATALYST BIOSCIENCES INC (US) | 2021-12-22 | — | — | EP | disclosed |
| US-11203749-B2 | Factor VII polypeptides that are modified and uses thereof | CATALYST BIOSCIENCES, INC. (US) | 2021-12-21 | — | — | US | disclosed |
| US-20210238260-A1 | GENE THERAPY FOR HEMOPHILIA B WITH A CHIMERIC AAV CAPSID VECTOR ENCODING MODIFIED FACTOR IX POLYPEPTIDES | GC BIOPHARMA CORP. (KR) | 2021-08-05 | — | — | US | disclosed |
| US-20210230570-A1 | MODIFIED FACTOR IX POLYPEPTIDES AND USES THEREOF | GC BIOPHARMA CORP. (KR) | 2021-07-29 | — | — | US | disclosed |
| WO-2021137245-A1 | CONUS-BASED TOXIN PEPTIDES, NUCLEIC ACIDS ENCODING SAME AND USES THEREOF IN MODULATING NMDA RECEPTORS | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2021-07-08 | — | — | WO | disclosed |
| US-10982203-B2 | Modified factor IX polypeptides and uses thereof | CATALYST BIOSCIENCES, INC. (US) | 2021-04-20 | — | — | US | disclosed |
| EP-3663399-A1 | MODIFIED FACTOR IX POLYPEPTIDES AND USES THEREOF | Catalyst Biosciences, Inc. (US) | 2020-06-10 | — | — | EP | disclosed |
| US-20200140840-A1 | FACTOR IX VARIANTS AND METHODS OF USE THEREFOR | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2020-05-07 | — | — | US | disclosed |
| WO-2001064748-A1 | ANTIBODIES BINDING A GAMMA CARBOXYGLUTAMIC ACID DISPLAYING EPITOPE | PROTEASE AB (SE) | 2001-09-07 | — | — | WO | disclosed |
| WO-2001016166-A2 | POLYPEPTIDES, COMPRISING IL-6 LIGAND-BINDING RECEPTOR DOMAINS, AND RELATED NUCLEIC ACIDS, ANTIBODIES, COMPOSITIONS, AND METHODS OF USE | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2001-03-08 | — | — | WO | disclosed |
| EP-0624199-B1 | METHODS FOR PRODUCING THROMBIN | ZYMOGENETICS INC (US) | 1999-05-06 | — | — | EP | disclosed |
| US-5527692-A | COMPRISING ACTIVATED RECOMBINANT GLA-DOMAINLESS PROTHROMBIN, WHICH IS CLEAVABLE TO THROMBIN | ZYMOGENETICS, INC. (US) | 1996-06-18 | — | — | US | disclosed |
| US-5502034-A | EXPRESSION OF THROMBIN PRECURSOR IN HOST CELL, TREATMENT OF BLEEDING DISORDERS | ZYMOGENETICS, INC. (US) | 1996-03-26 | — | — | US | disclosed |
| US-5476777-A | DNA construct directing expression of thrombin precursor, including transcriptional promoter, DNA segment encoding gla-domainless prothrombin, transcriptional terminator | ZYMOGENETICS, INC. (US) | 1995-12-19 | — | — | US | disclosed |
| EP-0624199-A1 | METHODS FOR PRODUCING THROMBIN | ZYMOGENETICS, INC. (US) | 1994-11-17 | — | — | EP | disclosed |
| WO-1993013208-A1 | METHODS FOR PRODUCING THROMBIN | ZYMOGENETICS, INC. (US) | 1993-07-08 | — | — | WO | disclosed |
| US-5225537-A | METHODS FOR PRODUCING HYBRID PHOSPHOLIPID-BINDING PROTEINS | ZYMOGENETICS, INC. (US) | 1993-07-06 | — | — | US | disclosed |
| WO-1991009953-A1 | METHODS FOR PRODUCING HYBRID PHOSPHOLIPID-BINDING PROTEINS | ZYMOGENETICS, INC. (US) | 1991-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238260-A1 | GENE THERAPY FOR HEMOPHILIA B WITH A CHIMERIC AAV CAPSID VECTOR ENCODING MODIFIED FACTOR IX POLYPEPTIDES | F13B, F9, F13A1 | ENPEP 1051/4885GRIK1 4633/4885GRIK2 4649/4885 |
| US-20230192896-A1 | BISPECIFIC ANTIBODIES BINDING TO COAGULATION FACTOR IX AND COAGULATION FACTOR X | F9, F13B, F11 | ENPEP 292/4885GRIK1 4417/4885GRIK2 4474/4885 |
| US-10982203-B2 | Modified factor IX polypeptides and uses thereof | F9, F13B, F13A1 | ENPEP 159/4885GRIK1 4734/4885GRIK2 4771/4885 |
| US-11203749-B2 | Factor VII polypeptides that are modified and uses thereof | F7, F13B, HABP2 | ENPEP 303/4885GRIK1 4509/4885GRIK2 4363/4885 |
| US-20210230570-A1 | MODIFIED FACTOR IX POLYPEPTIDES AND USES THEREOF | F9, F13B, F8 | ENPEP 88/4885GRIK1 4667/4885GRIK2 4722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.